It is a fact of life that the patient's notes, by which the committee means the Lloyd George envelope, move on with the patient and may well be lost in the process. Even if it is not lost much effort and time will be expended retrieving it should litigation take place.
Doctors would be well advised to ignore this part of the BMA advice and keep separate records at the surgery.
DAVID ROBERTS
Lutterworth, Leicestershire LE17 6JZ *** The secretary of the BMA writes: The points raised by Dr Roberts were carefully considered by the General Medical Services Committee when preparing its second guidance on product liability. The lawyers advised that the appropriate place to record the necessary details of supply to patients was their clinical record and that only in the case of drug samples did batch numbers need to be noted. The full extent of the implications of this law for general practitioners is uncertain, but if they follow this guidance they are unlikely to be at risk.
Burns ofthe elderly in residential care
Scalding as a result of failure in supervision of the elderly in residential care is well described by the case reports of Mr L C Bainbridge and Mr M J M Black (13 August, p 472). Another risk which should be highlighted was brought to our attention by the death ofa disabled person from burns, when cushions on his wheelchair were set alight by a dropped cigarette. We wondered how many people died in this manner, confined to a wheelchair or easy chair within the protected environment of institutional care. Published figures do not identify these deaths, so we therefore contacted all 52 chief fire officers in England and Wales, requesting information on incidents from 1980 to 1985.
Forty seven authorities replied, but nine gave insufficient data. Twenty nine authorities had no recorded deaths from burns in institutional care in the circumstances outlined above. The remaining nine authorities recorded 19 such deaths over the five years. Seventeen of these deaths were said to have involved cigarettes, matches, or other smoking materials and one an electric fire. In one the cause was unknown.
Death in the restricted circumstances we outline is uncommon -probably five each year in England and Wales. Nevertheless, the nature of these deaths is so horrifying as to warrant attention. Smoking is the prime risk factor and all residents who smoke must be considered to be at risk. A 34 year old white homosexual man had been diagnosed as suffering from AIDS two years previously after developing weight loss, biopsy proved P carinii pneumonia, and Kaposi's sarcoma. He was also human immunodeficiency virus (HIV) positive and T4 cell depleted. He was taking co-trimoxazole twice daily when fever, generalised pruritus, and progressive weakness necessitated his admission.
The main new findings included pancytopenia with a hypocellular bone marrow, mild jaundice, hepatomegaly associated with the presence of hepatitis B core antibody, and a non-specific acute hepatitis seen in a liver biopsy specimen. His serum bilirubin concentration ranged from 34 to 82 [tmol/l, alkaline phosphatase activity from 600 to 800 IU/ml, transaminase activity from 250 to 350 IU/ml, and his prothrombin time was 70% of the control value. He had oral candidiasis. The results of renal function tests were normal, and fasting plasma glucose and insulin concentrations on admission were 4-9 mmol/l and 6-3 mU/l respectively.
All drugs were stopped, and cultures of bronchoalveolar lavage fluid over seven days yielded negative results. The patient's temperature increased, however, and he developed dyspnoca associated with auscultatory and radiographic findings suggestive of recurrent P carinii pneumonia. Intravenous co-trimoxazole was started and continued despite the appearance of a transient erythematous rash. No other drugs were administered concomitantly. Slight fasting hypoglycaemia developed on the fourth and fifth days of treatment (3 5 and 2-9 mmol/l respectively), but no action was taken. On the morning of the sixth day the patient fell off his bed and was found to be stuporous with no focal neurological signs. His plasma glucose concentration was 1-1 mmolUl, a simultaneous serum insulin concentration was 12 mU/l, with a raised C peptide concentration and a serum cortisol concentration of 340 Fg/l.
Intravenous dextrose rapidly improved his neurological state, and there were no further episodes of hypoglycaemia over several months. Oral co-trimoxazole was started, and his fever settled and pulmonary state improved. The patient died five months later, and at necropsy no insulinoma or other tumour that might have been associated with his hypoglycaemia was found.
With the increasing use of co-trimoxazole to treat P carinii pneumonia in patients with AIDS a particularly high incidence of adverse reactions to the drug has been noted.34 Signs of drug toxicity may appear in as many as 78% of patients with AIDS and P carinii pneumonia,4 compared with about 8% in a general population.' The most common adverse reactions were rash, fever, cytopenias, and hepatotoxicity; but hypoglycaemia has not been reported to our knowledge. The reason for the high frequency of side effects to co-trimoxazole in AIDS remains obscure, but higher serum sulphamethoxazole concentrations in AIDS may be partly responsible.5 In our patient high drug concentrations were likely, and the hepatitis contributed to this. Liver disease may have also exacerbated the hypoglycaemia by impairing hepatic glycogenolysis and gluconeogenesis,6 but this cannot have been the predominant factor as hypoglycaemic episodes did not recur.
Hypoglycaemia induced by co-trimoxazole is a rare but recognised adverse effect. Sulphonamides have some chemical resemblance to oral hypoglycaemic agents. Sulphamethoxazole displaces sulphonylurea drugs from their binding protein and may potentiate their effects.7 Similarly binding of sulphamethoxazole to pancreatic islet tissue mimicking the effect of sulphonylureas and stimulating insulin release seems to be possible, though it has not been documented previously. The serum insulin concentrations of 12 mU/l were inappropriately high for a severe hypoglycaemia and support the above mechanism, in conjunction with the effects of poor nutrition and hepatic dysfunction that are also common with AIDS, making these patients more likely to develop hypoglycaemia.
With the growing number of patients with AIDS treated with high doses of co-trimoxazole this adverse reaction may occur more often. The potential of cotrimoxazole to cause hypoglycaemia should be more widely recognised, and patients should be monitored for the possible appearance of hypoglycaemia associated with sulphamethoxazole.
Acute painful proximal myopathy associated with nalidixic acid Drs ANDREW J CARMICHAEL and ANTHONY M MARTIN (Renal Unit, Royal Infirmary, Sunderland SR2 7JE) write: Several drugs are known to cause myopathies, including an acute painful proximal myopathy,' but we are unaware of any reports implicating nalidixic acid.
A 53 year old woman with chronic pyelonephritis, controlled hypertension, and impaired renal function (urea 29 mmolIl, creatinine 345 zmol/l) was prescribed full dose nalidixic acid (Negram) 1 g four times a day for a urinary tract infection. She had never received this antibiotic previously. Within 24 hours of starting treatment she developed severe aching and weakness in the proximal muscles of the arms and legs. She stopped the treatment after taking four doses and her symptoms gradually resolved over the next three days. Her only concomitant therapy was amiloride hydrochloride and hydrochlorothiazide (Moduretic) two tablets a day, which she had taken regularly for two years, and this was continued. Serum potassium concentration was normal.
The Committee on Safety of Medicines has received five reports of myalgia associated with nalidixic acid (personal communication) and the Australian Drug Evaluation Committee a further three.2 Given the strong temporal relation between the myopathy and nalidix acid treatment in our patient and the substantial number of suspected reports, we think it would be appropriate to include nalidixic acid in the list of drugs capable of inducing a painful proximal myopathy. We also advocate adherence to the manufacturer's recommendation to reduce the dose in renal impairment, which may have contributed to this adverse reaction. A previously healthy 75 year old woman presented with an eight week history of cough, breathlessness, blackouts, and malaise. She had no past or recent symptoms of gastrointestinal or renal disturbances. She had received a 14 day course of the combination of atenolol and chlorthalidone, one tablet daily, until two days before admission, and seven 5 mg tablets of prochlorperazine in the week before admission (for "dizziness").
She was dehydrated, and her blood pressure was 110/60 mm Hg lying and 80/40 mm Hg sitting. Plasma electrolyte concentrations were: sodium 109 mmoltl, potassium 1-5 mmol/l, urea 6-8 mmol/l, and creatinine 51 mmol/l. After partial rehydration with 1 5 litres of isotonic saline and 121-5 mmol potassium chloride/i intravenously her plasma sodium and potassium concentrations were 118 and 2-4 mmol/l respectively, and osmolality was 259 mmol/kg. Simultaneous urinary values were 94 and 26 mmol/l and 532 mmol/kg. Calcium and glucose concentrations were normal.
A bronchoscopic biopsy specimen of a hilar mass showed small cell anaplastic carcinoma. After full rehydration over 27 days ectopic adrenocorticotrophic hormone secretion and adrenocortical insufficiency were excluded. Neither clinical nor biochemical electrolyte disturbance recurred during the remaining four months of her life, even though she received no further treatment.
The only known precipitating factor for the hypokalaemia was the short course of treatment with a low dose of chlorthalidone. Hypokalaemic tubular damage could have accounted for her severe salt and water loss, although inappropriate secretion of antidiuretic hormone may have contributed to her low serum osmolality as a secondary effect. Chlorthalidone has been reported to cause hypokalaemia, either alone or in combination with atenolol,' 2 but the low dose, brief exposure, and severity of electrolyte disturbance in this case suggest either an idiosyncratic response or a previously unrecognised susceptibility secondary to underlying mahgnancy.
